Kala Pharmaceuticals announces FDA approval of EYSUVIS for short-term treatment of dry eye disease

This article was originally published here

“The FDA approval of EYSUVIS as the first prescription therapy specifically developed to address the short-term treatment needs of people living with dry eye disease is a major

The post Kala Pharmaceuticals announces FDA approval of EYSUVIS for short-term treatment of dry eye disease appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply